-
公开(公告)号:PA8558201A1
公开(公告)日:2003-09-05
申请号:PA8558201
申请日:2002-11-22
Applicant: HOFFMANN LA ROCHE
Inventor: FLOHR ALEXANDER , RIEMER CLAUS , JAKOB-ROETNE ROLAND , NORCROSS ROGER DAVID
IPC: A61K31/428 , A61K31/429 , A61K31/44 , A61K31/5377 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P21/02 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P37/08 , A61P39/02 , C07D277/68 , C07D277/82 , C07D409/12 , C07D417/12 , C07D477/12 , C07D417/09
Abstract: LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL EN DONDE R ES HIDROGENO, - (CH2)N-FENILO, OPCIONALMENTE SUSTITUIDO POR HALOGENO, ALQUILO INFERIOR, ALCOXILO INFERIOR, TRIFLUOROMETILO O -N(R´)-C(O)-ALQUILO INFERIOR,-(CH2)N-PIRIDINILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CH2)N-C3-6-CICLOALQUILO, OPCIONALMENTE SUSTITUIDO POR HIDROXILO,-(CH2)N-N(R´) -C3-6-CICLOALQUILO,-(CH2)N-BENZO [1,3]-DIOXILO,-(CR´2)-TIOFENILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CR´2)N-TIAZOLILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CH2)N-C(O)-TIOFENILO, OPCIONALMENTE SUSTITUIDO POR HALOGENO,-(CH2)N-FURANILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CH2)N-C(O)-(CH2)N-TIOFENILO,-(CHR´)N-BENZOFURAN-2-ILO,-(CH2)N-BENZO[B]TIOFENILO,OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR, -(CH2)N-N(R´)-C(O)-FENILO, OPCIONALMENTE SUSTITUIDO POR HALOGENO O ALCOXILO INFERIOR, -(CH2)N-C(O)-FENILO, OPCIONALMENTE SUSTITUIDO POR ALCOXILO INFERIOR, -(CH2)N-C(O)-2, 3-DIHIDRO-BENZO[1,4]DIOXIN-6-ILO, -(CH2)N-N(R´)-C(O)-PIRIDINILO,-(CH2)N-TETRAHIDROFURANILO,-CH-BI-FENILO,-CH(FENIL)-PIRIDINILO, -(CH2)N-1-OXO-1-OXO-1, 3-DIHIDRO-ISOINDOL-2-ILO, -(CH2)N-1, 3-DIOXO-1,3-DIHIDRO-ISOINDOL -2-ILO, -(CH2)N-CH(FENIL)-TETRAHIDROPIRANILO, -(CH2)N-1-OXO-1,2,3,4-TETRAHIDRO-ISOQUINOLIN-3-IL O -(CH2)N-S-[1,3,4]TIAZOL-2-ILO, OPCIONALMENTE SUSTITUIDO POR AMINO; ES HIDROGENO O ALQUILO INFERIOR, INDEPENDIENTEMENTE UNO DEL OTRO EN EL CASO DE R´2; Y N ES 0,1,2,3 O 4; Y LAS SALES DE ADICION ACIDA FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. LOS COMPUESTOS DE FORMULA I TIENEN UNA BUENA AFINIDAD POR EL RECEPTOR A2A Y ESTOS SON POR LO TANTO UTILES EN EL TRATAMIENTO DE ENFERMEDADES, RELACIONADAS CON ESTE RECEPTOR.
-
公开(公告)号:PE07132003A1
公开(公告)日:2003-08-23
申请号:PE0011042002
申请日:2002-11-15
Applicant: HOFFMANN LA ROCHE
Inventor: RIEMER CLAUS , JAKOB-ROETNE ROLAND , NORCROSS ROGER DAVID , FLOHR ALEXANDER
IPC: A61K31/4439 , A61K31/5377 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/32 , A61P25/34 , A61P25/36 , A61P29/00 , A61P37/08 , A61P43/00 , C07D417/12 , C07D417/14
CPC classification number: C07D417/12 , C07D417/14
Abstract: DERIVADOS BENZOTIAZOL DE NICOTINA O ISONICOTINA DE FORMULA IA O IB DONDE R1 ES FENILO, PIPERIDIN-1-ILO, MORFOLINILO; A ES O; R ES -(CH2)n-N(R'')-C(O)-ALQUILO, -(CH2)n-O-ALQUILO-, -(CH2)n-O-(CH2)n-O-ALQUILO, (CH2)n-MORFOLINILO, ENTRE OTROS; A ES -N(R')-; R ES ALQUILO, CICLOALQUILO C4-C6; -(CH2)n-O-ALQUILO, -(CH2)n-PIRIDINILO, -(CH2)n-PIPERIDINILO, -(CH2)n-FENILO, ENTRE OTROS; R' Y R'' SON H, ALQUILO; n ES 1-2; A ES -CH2-; R ES -N(R´´)-(C2)m-O-ALQUILO, -N(R'')2, -S-ALQUILO, ENTRE OTROS; R'' ES H, ALQUILO; m ES 1-3; A Y R JUNTOS SON PIPERAZINILO CON ALQUILO, -C(O)-ALQUILO, PIPERIDINILO, MORFOLINILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-(2-METOXI-ETOXI)-N-(4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-ISONICOTINAMIDA, 2-ETOXI-N-(4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-ISONICOTINAMIDA, 2-METOXI-N-(4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-ISONICOTINAMIDA, 2-ISOPROPOXI-N-(4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-ISONICOTINAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS TIENEN AFINIDAD POR EL RECEPTOR DE ADENOSINA A2A Y SON UTILES COMO AGENTES NEUROPROTECTORES
-
公开(公告)号:PA8558001A1
公开(公告)日:2003-07-28
申请号:PA8558001
申请日:2002-11-14
Applicant: HOFFMANN LA ROCHE
Inventor: FLOHR ALEXANDER , JAKOB-ROETNE ROLAND , NORCROSS ROGER DAVID , RIEMER CLAUS
IPC: A61K31/4439 , A61K31/5377 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/32 , A61P25/34 , A61P25/36 , A61P29/00 , A61P37/08 , A61P43/00 , C07D417/12 , C07D417/14
Abstract: LA PRESENTE INVENCION SE REFIERE A LOS COMPUESTOS DE FORMULA GENERAL EN DONDE R1 ES FENILO, PIPERIDIN-1-ILO O MORFOLINILO; A ES -O- Y R ES - (CH2) N-N(R' ') -C(O) -ALQUILO INFERIOR, -(C2)N-O-ALQUILO INFERIOR, -(CH2), N-O-(CH2)N-O-ALQUILO INFERIOR. ALQUILO INFERIOR, -(CH2)n-MORFOLINILO, -(CH2)n-FENILO, -(CH2)n- N (R' ') 2, -(CH2) N-PIRIDINILO, -(CH2)N-CF3, -(CH2)n-2-OXO-PIRROLIDINILO O C4-6-CICLOALQUILO; R' ' ES INDEPENDIENTEMENTE UNO DEL OTRO HIDROGENO O ALQUILO INFERIOR Y N ES 1 O 2; O A ES -N(R')-Y R ES ALQUILO INFERIOR, C4-6-CICLOALQUILO, -(CH2)N-O-ALQUILO INFERIOR, -(CH2)N-PIRIDINILO, -(CH2)N-PIPERIDINILO, -(CH2)N N-FENILO, -(CH2)N -N(R' ')-C(O)-ALQUILO INFERIOR, -(CH2)N-MORFOLINILO, 0-(CH2)N-N(R' ')2; R' Y R' ' SON INDEPENDIENTEMENTE UNO DEL OTRO HIDROGENO O ALQUILO INFERIOR Y N ES 1 O 2; O A ES -CH2- Y R ES -N(R' ')-(CH2)M-O-ALQUILO INFERIOR, -N(R' ')2, S-ALQUILO INFERIOR, O ES ACETIDINILO, PIRROLIDINILO O PIPERIDINILO, QUE ESTAN OPCIONALMENTE SUSTITUIDOS POR HIDROXILO O ALCOXILO INFERIOR O ES MORFOLINILO,- N(R'') -(CH2)M-C4-6-CICLOALQUILO, -N(R'')-(CH2)M-C(O)O-ALQUILO INFERIOR, -N(R'')-(CH2)M-C(O) OH, -2-OXO-PIRROLIDINILO, -N(R'')-C(O)O-ALQUILO INFERIOR, -O(CH2)M-O-ALQUILO INFERIOR O ALCOXILO; R'' ES INDEPENDIENTEMENTE UNO DEL OTRO HIDROGENO O ALQUILO INFERIOR Y M ES 1,2 Ó 3; O A ES-S-Y R ES ALQUILO INFERIOR; O A-R SON JUNTOS-PIPERAZINILO, SUSTITUIDO POR ALQUILO INFERIOR, -C(O)-ALQUILO INFERIOR O UN GRUPO OXO, O ES PIPERIDINILO, SUSTITUIDO POR ALCOXILO INFERIOR O HIDROXILO, O ES MORFOLINILO, SUSTITUIDO POR ALQUILO INFERIOR, O ES-C4-6-CICLOALQUILO, - AZETIDIN-1-ILO, OPCIONALMENTE SUSTITUIDO POR HIDROXILO O ALCOXILO INFERIOR, TIOMORFOLIN-1,1- POR DIOXO,- TETRAHIDOPIRANO O 2-OXA-5-AZA-BICICLO[2.2.1]HEPT-5-ILO; Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. SE HA ENCONTRADO QUE LOS COMPUESTOS DE FORMULA GENERAL I SON LIGANDOS DEL RECEPTOR DE ADENOSINA. ESPECIFICAMENTE, LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN UNA BUENA AFINIDAD POR EL RECEPTOR A2A Y ESTOS SON POR LO TANTO UTILES EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON ESTE RECEPTOR.
-
公开(公告)号:CA2470037A1
公开(公告)日:2003-06-26
申请号:CA2470037
申请日:2002-12-06
Applicant: HOFFMANN LA ROCHE
Inventor: POLI SONIA MARIA , JAKOB-ROETNE ROLAND , HUWYLER JOERG
IPC: A61K31/401 , A61K31/407 , A61P3/10 , A61P25/28 , A61P43/00 , C07D207/16 , C07D498/14
Abstract: The invention relates to compounds of formulae (I) or (IA), wherein R1 and R 2 are independently from each other and signify lower alkoxy, lower alkenyloxy , benzyloxy, hydroxy, -OCH(CH3)OC(O)-lower alkyl or OCH2C(O)N(R3)(R4), with th e proviso that only one of R1 or R2 may be hydroxy; R3 and R4 are independentl y from each other and signify hydrogen, lower alkyl, lower alkenyl or cycloalkyl; or R1 and R2 form together with the carbon atom, to which they a re attached the linking group X, wherein X is -O(CH2)nCH=CH(CH2)n0- or -O(CH2)m O- ; n is l, 2 or 3; and m is 4-8. as well as pharmaceutically acceptable salts of said compounds. Compounds of the present invention can be used for the treatment of diseases where Serum Amyloid P Component depletion has a beneficial effect, in particular in the treatment or prevention of all forms of central and systemic amyloidosis.
-
公开(公告)号:AU2002366194A1
公开(公告)日:2003-06-10
申请号:AU2002366194
申请日:2002-11-09
Applicant: HOFFMANN LA ROCHE
Inventor: FLOHR ALEXANDER , JAKOB-ROETNE ROLAND , NORCROSS ROGER DAVID , RIEMER CLAUS
IPC: A61K31/4412 , A61K31/5377 , A61P9/02 , A61P9/10 , A61P11/00 , A61P11/06 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P37/08 , A61P43/00 , C07D417/12 , C07D417/14
Abstract: The present invention relates to compounds of the formulawherein R is as defined herewithin. The compounds of formula I have a good affinity to the A2A receptor and therefore they may be used in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or against asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, aniticonvulsants and cardiaprotective agents for disorders such as coronary artery disease and heart failure.
-
公开(公告)号:AU2002352045A1
公开(公告)日:2003-06-10
申请号:AU2002352045
申请日:2002-11-18
Applicant: HOFFMANN LA ROCHE
Inventor: FLOHR ALEXANDER , JAKOB-ROETNE ROLAND , NORCROSS ROGER DAVID , RIEMER CLAUS
IPC: A61K31/428 , A61K31/429 , A61K31/44 , A61K31/5377 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P21/02 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P37/08 , A61P39/02 , C07D277/68 , C07D277/82 , C07D409/12 , C07D417/12 , C07D477/12
Abstract: A compound of the formulaA compound of formula I has a good affinity to the A2A receptor and is useful for the treatment of diseases mediated by this receptor.
-
公开(公告)号:CA2468311A1
公开(公告)日:2003-06-05
申请号:CA2468311
申请日:2002-11-21
Applicant: HOFFMANN LA ROCHE
Inventor: FLOHR ALEXANDER , JAKOB-ROETNE ROLAND , RIEMER CLAUS , NORCROSS ROGER DAVID
IPC: A61K31/428 , A61K31/5377 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P21/02 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P29/00 , A61P37/08 , A61P43/00 , C07D277/82 , C07D417/12 , C07D417/04
Abstract: The present invention relates to compounds of the general formula (I) wherei n R1 is hydrogen or lower alkyl; R2 is lower alkyl, -(CH2)n-O-lower alkyl, -C3 -6- cycloalkyl or -(CH2)n-NR'2; R' is hydrogen, lower alkyl or -(CH2)n-O-lower alkyl, independently from each other for R'2, or R'2 may form together with the N atom a pyrrolidine ring; n is l, 2 or 3; and to pharmaceutically acceptable acid addition salts thereof. It has surprisingly been found that the compounds of general formula I are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they are therefore useful in the treatment of diseases, related to this receptor.
-
公开(公告)号:PT915088E
公开(公告)日:2003-01-31
申请号:PT98119986
申请日:1998-10-22
Applicant: HOFFMANN LA ROCHE
Inventor: JAKOB-ROETNE ROLAND , NORCROSS ROGER DAVID , HERTEL CORNELIA , HOFFMANN TORSTEN
IPC: C07K5/078 , A61K31/00 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K38/08 , A61P3/00 , A61P3/10 , A61P9/04 , A61P9/10 , A61P25/00 , A61P25/28 , A61P43/00 , C07D207/16 , C07D207/22 , C07D207/277 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D521/00 , C07D417/06 , C07D413/12 , C07D419/12
Abstract: The invention relates to D-prolines of the formula wherein R is SH, benzyl or phenyl, optionally substituted by hydroxy or lower alkoxy or the group R' is hydrogen or halogen; X is -(CH2)n-; -CH(R )(CH2)n-; -CH2O(CH2)n-; -CH2NH-; benzyl, -C(R )=CH-; -CH2CH(OH)-; or thiazol-2,5-diyl; Y is -S-S-; -(CH2)n-; -O-; -NH-; -N(R )-; -CH=CH-; -NHC(O)NH-; - N(R )C(O)N(R )-; -NÄCH2C6H3(OCH3)2Ü-; -N(CHC6H5)-; -N(CH2C6H5)C(O)N(CH2C6H5)-; -N(alkoxyalkyl)-; -N(cycloalkyl-methyl)-; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen,1,3-phenylen and 1,4-phenylen, wherein the phenylen groups are optionally substituted by 1 - 4 substituents, selected from halogen, lower alkyl, lower alkoxy, hydroxy, carboxy, -COO-lower alkyl, nitrilo, 5-tetrazol, (2-carboxylic acid-pyrrolidin-1-yl)-2-oxo-ethoxy, N-hydroxycarbamimidoyl, 5-oxo-Ä1,2,4Üoxadiazolyl, 2-oxo-Ä1,2,3,5Üoxathiadiazolyl, 5-thioxo-Ä1,2,4Üoxadiazolyl and 5-tert-butylsulfanyl-Ä1,2,4Üoxadiazolyl; X' is -(CH2)n-; -(CH2)nCH(R )-; -(CH2)nOCH2-; -NHCH2-; benzyl, -CH=C(R )-; -CH(OH)CH2; or thiazol-2,5-diyl; R is lower alkyl, lower alkoxy or benzyl and n is 0-3, and to pharmaceutically acceptable salts and mono- and diesters thereof. The D-prolines of formula I-A and I-B can be used in the treatment or prevention of all forms of central and systemic amyloidosis.
-
公开(公告)号:NO20021077D0
公开(公告)日:2002-03-05
申请号:NO20021077
申请日:2002-03-05
Applicant: HOFFMANN LA ROCHE
Inventor: TROTTMANN GERDA HUBER , HUNKELER WALTER , JAKOB-ROETNE ROLAND , KILPATRICK GAVIN JOHN , NETTEKOVEN MATTHIAS HEINRICH , RIEMER CLAUS
IPC: C07D213/73 , A61K31/437 , A61K31/4418 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K31/635 , A61P9/10 , A61P11/06 , A61P11/16 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/28 , A61P25/30 , A61P37/08 , A61P43/00 , C07D409/04 , C07D471/04 , C07D519/00 , C07D
Abstract: The invention relates to compounds of formulawhereinR1 is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH2)nOH, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenyl group, or isphenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is-O(CH2)n,phenyl, benzofuryl, indolyl or benzothiophenyl, or is-S-lower alkyl;R2 and R4 are independently from each other hydrogen, cyano or -S(O)2-phenyl;R3 is hydrogen, halogen or isa 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH2)n-aryl, hydroxy, halogen, lower alkoxy, morpholinyl, amino, lower alkylamino or -C(O)NR'2, and wherein R' is lower alkyl or hydrogen, or isphenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF3, -OCF3, -NHC(O)lower alkyl, cyano, -C(O)-lower alkyl, -C(O)O-lower alkyl, -S-lower alkyl, -S(O)2NH-phenyl, -S(O)2-methylpiperazinyl; or is-NR'R'', wherein R' and R'' are independently from each other hydrogen, -(CH2)nphenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, -CH(lower alkyl)-phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is-O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, -O-tetrahydronaphthalenyl or -O-CH2-6-methyl-pyridin-2-yl; or is-benzo[1,3]dioxolyl, -1H-indol-5-yl, naphthyl, benzofuran-2-yl, 1,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morpholinyl;R5 is -NR2, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH2)n-phenyl or -COO(CH2)n-phenyl, wherein the phenyl ring is optionally substituted by CF3, lower alkoxy, halogen or lower alkyl, -CO(CH2)3-NHCO-lower alkoxy, -(CH2)n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF3 or halogen, or is 4,5-dihydro-1H-imidazol-2-yl-benzoic acid, 1,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl-benzoic acid;n is 0-4and their pharmaceutically acceptable salts
-
公开(公告)号:GR3033815T3
公开(公告)日:2000-10-31
申请号:GR20000401515
申请日:2000-06-29
Applicant: HOFFMANN LA ROCHE
Inventor: BORGULYA JANOS , BRUDERER HANS , JAKOB-ROETNE ROLAND , ROEVER STEPHAN
IPC: A61K31/42 , A61K31/421 , A61K31/422 , A61K31/425 , A61K31/44 , A61K31/445 , A61P25/00 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/26 , A61P25/28 , C07D263/24 , C07D413/04 , C07D413/10 , C07D413/14
Abstract: The invention relates to oxazolidin-2-one derivatives of the formula wherein R is hydrogen or lower alkyl; X is cycloalkenyl; bicyclo[2.2.1]hept-2-yl, opt. substituted by phenyl-2-oxo-5-methoxymethyloxazolidinyl; bicyclo[2.2.1]hept-5-en-2-yl; adamantyl; or cycloalkyl or piperidine, optionally mono- or polysubstituted by halogen, amino, lower alkyl, nitrile, an oxo group, hydroxyimino, ethylenedioxy or by -OR , wherein R is -CH(C6H5)2, -(CH2)nC6H5, lower alkyl, hydrogen, - (CH2)nNHCOCH3, -(CH2)nNH2, -(CH2)nSOCH3, -(CH2)nCN, -(CH2) nSCH3, -(CH2)nSO2CH3, -CO-lower alkyl, -COC6H5, opt. substituted by an oxazolidinyl group: or by =CR R , wherein R is hydrogen or lower alkyl; R is hydrogen, nitrile, lower alkyl, phenyl or COO-lower alkyl; or by -(CH2)nR , wherein R is nitrile, amino, -NHCOCH3, -COC6H5Hal, phenyl or hydroxyl; or by -COR , wherein R is lower alkyl, -CH=CH-C6H5, -C6H5CF3, -O-C(CH3)3 or -O-lower alkyl; or by -NR R , wherein R is hydrogen or -COCH3; R is -COCH3, benzyl or -(CH2)nNHCOC6H4Hal; n is 1-3; Y is -CH= or -N=; Y is -CH=, -C(OH)=, -C(NO2)=, -C(NH2)=, -C(Hal)= or -N= and pharmaceutically acceptable salts of basic compounds of the formula I with acids. These novel compounds and their pharmaceutically acceptable salts can be used for the prevention or control of depressive states, panic and anxiety states, cognitive disorders and neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.
-
-
-
-
-
-
-
-
-